InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,466.22
(
-0.13%
)
US TECH 100
19,275.20
(
0.09%
)
Dow Jones
39,140.83
(
0.02%
)
Brent Oil
84.44
(
-0.67%
)
Bitcoin
63,690.82
(
-1.74%
)
Post# of 92948
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

rocky301

Send PM Follow Ignore
Followers 110
Posts 6480
Boards Moderated 0
Alias Born 05/01/2003

rocky301

Re: jonnyboy76 post# 40590

Tuesday, 02/14/2012 7:16:44 PM

Tuesday, February 14, 2012 7:16:44 PM

Post# of 92948
jonny,


both have potential if successful, only clinical trials will determine who has what and if it works. To date ACT has only treated one dryAMD patient. ACT stated in their Lancet report PR
(below) that "Engraftment and increasing pigmentation were not detected in the dry AMD patient." ACT is in the very early stages and StemCells Inc hasn't begun yet. Clinical trials are long, this will be no different...
http://www.advancedcell.com/news-and-media/press-releases/act-publishes-first-report-of-embryonic-stem-cell-esc-derived-cells-transplanted-into-patients/index.asp
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up